on Galimedix, Inc.
Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101
Galimedix Therapeutics presented Phase 1 study results for GAL-101 at the Clinical Trials on Alzheimer’s Disease 2025 conference. GAL-101, an oral small molecule, displayed excellent safety and pharmacokinetics in a study involving around 100 healthy volunteers. Importantly, the drug penetrated the blood-brain barrier, confirming its potential for treating Alzheimer’s disease. No dose-limiting adverse events were observed.
The Phase 2 study will include cognitive functional endpoints and biomarker assessments. Continuous at-home cognitive monitoring will capture early improvements due to GAL-101's rapid inactivation of toxic amyloid beta species. The study's positive outcomes support the advancement to Phase 2, with hopes that GAL-101 could become a standard treatment for Alzheimer’s across all stages.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news